Researchers disclosed robust antitumor activity for M‑3554, an antibody–drug conjugate (ADC) targeting GD2 that uses a β‑glucuronide linker and an exatecan payload, in neuroblastoma and soft-tissue sarcoma preclinical models. The construct was engineered to reduce anti‑GD2 antibody–associated pain while delivering potent payload activity. The preclinical profile supports further translational work toward clinical testing in GD2‑expressing solid tumors.